LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to
changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today
announced upcoming presentations at the Oligonucleotide Therapeutics Society (OTS) annual meeting to be held from September 30 –
October 3, 2018 in Seattle, WA.
Oral presentation on QR-110 clinical data in LCA10
David Rodman, MD, EVP of R&D of ProQR, will give a presentation on the recent clinical data from the QR-110 program for
Leber’s congenital amaurosis type 10 (LCA10).
Presentation title: Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited
retinal dystrophy in adults and children with LCA10
Presenter: David Rodman, MD, EVP of R&D of ProQR
Presentation: Wednesday, October 3 at 5 pm PT
Session: Session X: Late-breaking clinical studies
Poster presentation on Axiomer® RNA editing technology
A presentation will be delivered by Julien Boudet, PhD, Sr. scientist computational analytics of ProQR on the
Axiomer® RNA editing technology.
Poster title: Structure-based computational approach for optimizing oligonucleotides for A-to-I
editing
Poster #: 29
Presenter: Julien Boudet, PhD, Sr. scientist computational analytics of ProQR
Poster presentation: Sunday, September 30 between 6–8 pm PT
Session: Poster session 1
About QR-110
QR-110 is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of Leber’s
congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. The
p.Cys998X mutation is a substitution of one nucleotide in the pre-mRNA that leads to aberrant splicing of the mRNA and
non-functional CEP290 protein. QR-110 is designed to restore normal (wild-type) CEP290 mRNA leading to the production of normal
CEP290 protein by binding to the mutated location in the pre-mRNA causing normal splicing of the pre-mRNA. QR-110 is intended to be
administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the
European Union and received fast-track designation by the FDA.
About Leber’s Congenital Amaurosis 10
Leber’s congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children and consists of a
group of diseases of which LCA10 is the most frequent and one of the more severe forms. LCA10 is caused by mutations in the CEP290
gene, of which the p.Cys998X mutation is the most common. LCA10 leads to early loss of vision causing most people to lose their
sight in the first few years of life. To date, there are no treatments approved or other products in clinical development that
treat the underlying cause of the disease. Approximately 2,000 people in the Western world have LCA10 because of this mutation.
About Axiomer® Technology Platform
ProQR is pioneering a next-generation RNA technology called Axiomer®, which could potentially yield a new class of
medicines for genetic diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA
in a highly specific and targeted way using molecular machinery that is present in human cells. The Axiomer® EONs are
designed to recruit an endogenously expressed RNA editing system called ADAR, which it can direct to the change of an Adenosine (A)
to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G).
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based
on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar
expressions. Such statements include those relating to our participation at the OTS annual meeting. Forward-looking statements are
based on management's beliefs and assumptions and on information available to management only as of the date of this press release.
Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including,
without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission,
including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should
not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com
Media Contact:
Sara Zelkovic
LifeSci Public Relations
T: +1 646 876 4933
Sara@lifescipublicrelations.com
